Managing Primary Hyperparathyroidism: What Are Your Options?

Published: Apr 03, 2024

Managing primary hyperparathyroidism effectively can prevent serious complications like osteoporosis and kidney stones.

Surgical Treatments

Surgery is often the first line of treatment for primary hyperparathyroidism, especially when symptoms are severe. The most common surgery involves removing the overactive parathyroid gland. In some cases, minimally invasive techniques can be used, reducing recovery time and scarring.

Non-Surgical Approaches

For patients who are not candidates for surgery, medication can help manage calcium levels. Drugs like calcimimetics mimic calcium in the bloodstream, helping to reduce PTH secretion. Additionally, bisphosphonates may be prescribed to protect bone health by slowing down bone resorption.

Primary hyperparathyroidism is a condition characterized by an overproduction of parathyroid hormone, leading to elevated calcium levels and potential complications such as osteoporosis and kidney stones.

Monitoring and Lifestyle Changes

Regular monitoring of calcium levels is crucial in managing primary hyperparathyroidism. Patients are also encouraged to maintain a balanced diet rich in calcium and vitamin D to support bone health. Staying hydrated and avoiding high-calcium foods can also help manage symptoms.

Frequently Asked Questions

Surgery to remove the overactive gland is the most common treatment.

Yes, medications and lifestyle changes can help manage the condition.

Diet and hydration can manage symptoms and support bone health.

Surgery can often cure the condition by removing the problematic gland.

Key Takeaways

Effective management of primary hyperparathyroidism involves a combination of surgical and non-surgical approaches tailored to the individual.

Get started by consulting Doctronic about the best treatment options for you.

Related Articles

References

Brown EM. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 1991; 71:371.

Sengul Aycicek G, Aydogan BI, Sahin M, et al. Clinical Impact of p27Kip1 and CaSR Expression on Primary Hyperparathyroidism. Endocr Pathol 2018; 29:250.

Always discuss health information with your healthcare provider.